Print
The rising cost of specialty drugs continues to be a battleground between drugmakers, healthcare providers, and payers over the cost of innovative therapies. Express Scripts recently did a study that suggested more than $9 billion will be wasted by U.S. Health Plan sponsors in 2015 and separately added 66 exclusions to its formulary that included several newly approved and high profile drugs. We spoke to Steve Miller, chief medical officer of Express Scripts, about striking a balance between innovation and costs, how waste in the system can be addressed, and whether and when biosimilars will begin to curb rising costs.
August 14, 2014
http://www.burrillreport.com/article-payers_look_to_curb_spending_on_specialty_drugs.html
